Pharma Industry Snubs Chancellor Merz – Only Sanofi CEO Garijo Shows Up

TVS News AI, editorially supervised, presents Pharma Industry Snubs Chancellor Merz – Only Sanofi CEO Garijo Shows Up.

When an entire industry turns down an invitation from the Federal Chancellor, that carries weight. According to a report by Handelsblatt, nearly all major pharmaceutical companies declined the invitation to the government's investment summit. The only senior industry figure to appear was Belén Garijo, CEO of pharmaceutical giant Sanofi.

The symbolic gesture is heavy with meaning: an industry that could pour billions into new plants, active ingredients, and clinical trials in the coming years simply gave the Chancellor the cold shoulder. Garijo traveled there anyway – and used the stage to speak plainly.

"We are not a cost factor" – Garijo's message, in her own words

We are not a cost factor.

Garijo directs this sentence at Friedrich Merz. With it, the pharma chief pushes back against a view in which drug manufacturers appear in political debate primarily as a burden on the health insurance system – not as partners in a research-intensive industry. That this line lands precisely at the investment summit is no coincidence: anyone looking to invest billions in sites wants to know in advance whether politicians are on board.

Sanofi itself evidently considers it – as the Handelsblatt reporting indicates – "logical to invest here". What sums, which sites, and what timelines lie behind that statement, however, cannot be gleaned from the available reporting.

Why the industry slammed the door in the Chancellor's face

A collective rejection of this magnitude doesn't come out of nowhere. When nearly the entire industry declines an invitation from the Federal Chancellor, the refusal is the sharpest signal an industry can send to the political leadership. Garijo breaks that silence – as the only one to do so.

That she, of all people, came is no accident. In an industry that is staying away en masse, anyone who dares show up at the Chancellor's event is making a deliberate statement: Sanofi is willing to engage in dialogue – even if the message is an uncomfortable one.

What this means for you

The scene may look small, but it is a yardstick. When Germany's pharmaceutical industry won't even drop by the Federal Chancellor's office for a joint photo, it's no longer about courtesy – it's about trust. And trust is the currency in which investment decisions worth billions are negotiated. Garijo's lone appearance at the investment summit is therefore less a solo statement than a warning shot across the bow.